All In Biotech

Free tool

FAERS Monitor: Xdemvy

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217603 or its brand name (Xdemvy, Lotilaner). Reports on generic versions are filed under their own applications.

Reports

3,918

Serious

320

8% of reports

Hospitalization

79

Death reported

39

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye irritation491
  • off label use417
  • ocular hyperaemia322
  • product use issue315
  • condition aggravated280
  • eye pain277
  • vision blurred267
  • therapy interrupted253
  • wrong technique in product usage process252
  • eye pruritus214
  • drug ineffective199
  • product prescribing issue167
  • instillation site irritation149
  • lacrimation increased144
  • eye swelling130

Reports by year received

View as table
YearReports
20181
20201
20221
202322
2024776
20251,254
20261,863

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,241 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
instillation site irritationSignal149773.5653.399,814
eye irritationSignal49146.242.521,532
product prescribing issueSignal16741.535.76,510
ocular hyperaemiaSignal32236.733.011,085
eye pruritusSignal21434.430.26,874
eye painSignal27726.523.66,751
lacrimation increasedSignal14425.721.93,383
therapy interruptedSignal25319.116.94,313
eye swellingSignal13018.815.92,172
vision blurredSignal26710.59.32,285
product use issueSignal3159.08.12,252
wrong technique in product usage processSignal2526.75.91,222
condition aggravatedSignal2804.94.4890
off label useSignal4172.62.3411
drug ineffective1990.80.79

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.